Evidence map›Paper›PMID 10760691›Full record

ArticleJapanese journal of cancer research : Gann2000

Characterization of high-grade neuroendocrine tumors of the lung in relation to menin mutations.

N Haruki, Y Yatabe, W D Travis, S Nomoto, H Osada, S Nakamura, A Nakao, Y Fujii, T Takahashi

Open access · greenAbstract read
In one paragraph

Article in Japanese journal of cancer research : Gann, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Menin in Cancer.Genes · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

N HarukiLaboratory of Ultrastructure Research, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan.
Y Yatabe
W D Travis
S Nomoto
H Osada
S Nakamura
A Nakao
Y Fujii
T Takahashi
Aichi Cancer Center · JPNagoya City University · JPArmed Forces Institute of Pathology · USNagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been suggested that mutations in the menin gene play a role in the development of multiple endocrine neoplasia type 1 (MEN1)-associated and of sporadic forms of low- and intermediate-grade neuroendocrine tumors of the lung. In the present study, eight tumor specimens of large cell neuroendocrine carcinoma (LCNEC) and 13 of small cell lung cancer (SCLC), which represent a high-grade category of neuroendocrine tumors, were examined for the potential involvement of menin alterations as well as for the expression of various neuroendocrine markers and p53 and Rb abnormalities. All specimens expressed multiple neuroendocrine markers as expected and almost invariably carried p53 and Rb alterations. Unexpectedly, however, mutations in the menin gene were not detected in any of the high-grade neuroendocrine tumors examined. We thus conclude that menin mutations do not play a crucial role in the pathogenesis of high-grade subsets, in contrast to their suggested significant role in the development of low- and intermediate-grade subsets. Interestingly, loss of heterozygosity (LOH) in the menin gene appeared to be more prevalent in LCNEC (50%) than in SCLC (22%), suggesting a possible distinction between SCLC and LCNEC.

Indexed as

Proto-Oncogene ProteinsCarcinoma, Large CellCarcinoma, Small CellDNA PrimersGenes, Tumor SuppressorGenetic MarkersHumansLung NeoplasmsMultiple Endocrine Neoplasia Type 1Neoplasm ProteinsDNA PrimersGenetic MarkersMEN1 protein, humanNeoplasm ProteinsProto-Oncogene Proteins

Identifiers

PMID10760691
PMCPMC5926365
OpenAlexW2060165156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.